494
Participants
Start Date
December 23, 2011
Primary Completion Date
October 3, 2013
Study Completion Date
October 15, 2013
CXA-201 and metronidazole
CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
Meropenem
Meropenem IV infusion (1000mg q8h) for 4-14 days
Springfield
Boston
Robbinsdale
Columbus
Ciudadelo-Buenos Aires
General Rodríguez
La Plata
Loma Hermosa
Luján
Merlo
Tandil
Vicente López
Paraná
Corrientes
Córdoba
Santa Fe
Pleven
Sofia
Varna
Temuco
Santiago
Split
Zagreb
Kohtla-Järve
Tallinn
Tartu
Freiburg im Breisgau
Heidelberg
Gyula
Szeged
Szentes
Győr
Zalaegerszerg
Budapest
Kaposvár
Kecskemét
Vác
Kfar Saba
Tel Litwinsky
Beer Yahkov
Haifa
Liepāja
Riga
Kaunas
Klaipėda
Šiauliai
Vilnius
Chisinau
Krakow
Lubin
Wołomin
Szczecin
Lodz
Belgrade
Krafujevac
Niš
Novi Sad
Wŏnju
Incheon
Suwon
Seoul
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY